Business Context and Reporting Period
Cormedix Inc. filed this Form 8-K on January 10, 2013, to report the entry into a Material Definitive Agreement. The company is developing Neutrolin, a product for the prevention of catheter-related infections in dialysis and non-dialysis markets, and anticipates receiving CE Mark approval in Europe in the first quarter of 2013.
Key Financial Metrics
This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The only financial metric disclosed is the compensation structure for the new agreement: Cormedix will pay MKM Co-Pharma GmbH €680 per day for the work of a national sales manager, plus reimbursement for approved expenses such as travel and accommodation.
Material Changes
The primary material change is the execution of an agreement with MKM Co-Pharma GmbH to market Neutrolin in Germany. This agreement establishes a three-phase marketing plan:
- Phase 1 (Jan–Mar 2013): Market review, test sales, wholesaler negotiations, and sales projections.
- Phase 2 (Apr–May 2013): Product launch and sales generation, contingent on CE Mark approval.
- Phase 3 (Post-May 2013): Sales growth and advertising plan expansion.
Outlook, Risks, and Contingencies
Management commentary indicates a reliance on the anticipated Q1 2013 CE Mark approval to proceed with the full product launch in Germany. Key risks and contingencies include:
- Regulatory Risk: The second phase of the marketing plan is conditional on receiving CE Mark approval.
- Termination Liability: If Cormedix terminates the agreement early due to its own breach, liquidation, or insolvency, it must pay MKM for services rendered for up to three months following notice.
- Performance Risk: MKM is obligated to replace the sales manager if performance complaints are not resolved within four weeks.
- Contractual Restrictions: Cormedix cannot directly hire the sales manager without paying a fee to MKM.
Investor Verification Checklist
- Verify the status of the CE Mark approval for Neutrolin in Europe.
- Confirm the total projected cost of the agreement based on the €680 daily rate and expected duration.
- Review the full text of the agreement (Exhibit 10.22) for specific definitions of "good cause" and termination clauses.
- Assess the progress of the Phase 1 market review and test sales in Germany.